GLP-1s and Testosterone: What Men Should Know

As GLP-1 medications like semaglutide have become more widely used for weight management, a specific question has come up more and more from men: what does this do to my testosterone?

It's a reasonable thing to ask. Testosterone plays a role in energy, mood, muscle, libido, and overall metabolic health, and it's closely tied to weight. This guide walks through what the current evidence suggests about GLP-1s and testosterone in men, why the connection exists, and — importantly — where the science is still early and uncertain.

This article is educational and is not a substitute for medical advice. Semaglutide is a prescription medication, and decisions about it (and about testosterone) should be made with a licensed healthcare provider.

First: the weight-testosterone link

To understand how GLP-1s might affect testosterone, it helps to start with a well-established fact: in men, excess weight and low testosterone often go together.

Body mass index is inversely related to testosterone — as weight rises, testosterone tends to fall. Excess fat tissue, particularly around the abdomen, contributes to what's called obesity-related (or functional) hypogonadism: lower testosterone driven largely by excess weight rather than a primary problem with the testes. It's common and often under-recognized. Some research in men with significant obesity has found functional hypogonadism in a majority of patients.

The encouraging flip side: weight loss is consistently associated with rising testosterone. Both moderate and larger reductions in BMI have been linked to meaningful increases in testosterone levels. This is the backdrop against which the GLP-1 question makes sense.

What the GLP-1 evidence suggests

Because GLP-1 medications produce significant weight loss, researchers have looked at whether that translates into higher testosterone in men. The early signals are encouraging, but it's important to be clear about how early they are.

• A study presented at the Endocrine Society's 2025 annual meeting reported that men with obesity or type 2 diabetes on GLP-1 medications saw both significant weight loss and improved testosterone over roughly 18 months — with average total testosterone rising notably as participants lost weight.

• A small randomized trial in men with type 2 diabetes and functional hypogonadism found that semaglutide was associated with improvements in testosterone-related symptoms and even sperm morphology over 24 weeks.

• Some cohort data in men with diabetes has suggested GLP-1 use is associated with better erectile function, possibly through effects on weight, blood vessels, and inflammation.

The common thread across the research: the testosterone benefit appears to be driven primarily by weight loss, rather than by GLP-1s acting directly on the hormone system. In other words, it may be less "semaglutide raises testosterone" and more "losing weight raises testosterone, and semaglutide helps you lose weight." Researchers are still investigating whether there's any additional direct effect.

The important caveats

This is an emerging area, and honesty about its limits matters more than a clean headline:

• The studies are early and often small. Conference presentations and small trials are useful signals, not settled conclusions. Larger, longer studies are needed.

• The evidence is not uniformly positive. At least one database analysis raised the possibility of an association between semaglutide use and erectile dysfunction in some non-diabetic men — a reminder that the picture is still being worked out and individual responses vary.

• GLP-1s are not a testosterone treatment. They are not authorized as a therapy for low testosterone. Any testosterone benefit seen in research is a secondary effect of weight loss, not the reason the medication exists.

GLP-1s vs. testosterone replacement therapy

Some men wondering about this are really asking a bigger question: if my testosterone is low and I'm carrying extra weight, what's the right approach?

That's genuinely a clinical decision, and the two options work differently. Testosterone replacement therapy (TRT) directly raises testosterone but doesn't address the underlying weight. Weight loss — including via a GLP-1, when appropriate — targets the root cause of obesity-related low testosterone and brings broader metabolic benefits. In some men, addressing weight is the more logical first step; in others, low testosterone needs direct evaluation and treatment. There's no one-size answer, which is exactly why this is a conversation to have with a provider rather than a decision to make from an article.

The bottom line

The current evidence suggests that GLP-1 medications may help improve testosterone in men — but largely as a downstream benefit of weight loss, and within a body of research that's still early. GLP-1s aren't a testosterone therapy, the data isn't uniform, and individual responses differ.

If you're a man dealing with weight and concerns about testosterone, energy, or sexual health, the most useful step is an assessment that looks at all of it together. At Kinro, weight management and men's health are handled side by side, so these connected concerns can be evaluated as one picture rather than in isolation.

Start your Consultation

This article is for general educational purposes and does not constitute medical advice, diagnosis, or treatment. Semaglutide is a prescription medication authorized by Health Canada for chronic weight management; it is not authorized as a treatment for low testosterone. The research described here is emerging and evolving. Individual results vary. Always consult a licensed healthcare provider about your specific situation and review the product monograph before starting any treatment.